The REQUITE analysis followed 1,097 men diagnosed with non-metastatic prostate cancer who received radiotherapy in 2014–2016 and completed the Multidimensional Fatigue Inventory (MFI) repeatedly up to five years. Investigators defined prevalent fatigue using the 75th percentile from a German general population sample of men aged 60 and older; this cut-off was applied to all five MFI dimensions (general fatigue, physical fatigue, mental fatigue, reduced activity, reduced motivation). The study team collected baseline patient characteristics before radiotherapy and then used these for predictive analyses of long-term fatigue two years later.
Data indicated that fatigue is common and persistent. The cohort showed that 72% (785/1,097) of patients reported fatigue in at least one MFI dimension at some point from before radiotherapy through five years of follow-up. At two years post-radiotherapy, 45% (367/816) of respondents met the fatigue threshold for at least one dimension. These figures convey both early-onset and sustained symptom burden in a majority of men undergoing radiotherapy for non-metastatic disease.
The study team used logistic regression to link pre-radiotherapy variables with each fatigue dimension measured two years later. Baseline fatigue level emerged as the strongest predictor across dimensions, with reported odds ratios ranging from 4.7 to 9.0. Depression before radiotherapy carried an approximate OR of 2.5 for later fatigue. Metabolic and vascular comorbidities were implicated as well: diabetes showed ORs between 1.8 and 2.2, and hypertension between 1.6 and 1.8 for long-term fatigue outcomes. Body mass index (BMI) was associated with increased odds (OR range: 1.8–2.2). Investigators reported these variables as statistically significant predictors across multiple MFI dimensions.
Beyond single time-point prevalence, the study explored temporal patterns. Latent class growth analysis revealed discrete fatigue trajectories up to two years post-radiotherapy. The cohort included subgroups with persistently low fatigue, improving fatigue, and a high-fatigue trajectory. Multinomial regression associated depression, higher BMI, and receipt of pelvic radiotherapy with a higher probability of belonging to the high-fatigue trajectory. The study team therefore linked baseline psychological, anthropometric, and treatment factors to longitudinal symptom courses.
Investigators compared MFI scores up to five years with German population reference values and with fatigue outcomes in women with non-metastatic breast cancer within the REQUITE cohort. The abstract reports that multidimensional fatigue was assessed in these comparative contexts, but it did not report detailed comparative statistics or effect sizes in the summary. The reader should note that full comparison tables and subgroup statistics were not included in the abstract and would require consultation of the full article for complete numerical contrasts.
Authors noted that early fatigue assessments and routine documentation of self-reported comorbidities and BMI offer prognostic information beyond simple symptom detection. The cohort showed that pre-radiotherapy fatigue measurement predicted long-term outcomes strongly; depression and BMI added further risk stratification. These findings indicate that the MFI—a multidimensional measure—can identify discrete domains (physical, mental, activity, motivation) that might be targeted with dimension-specific interventions. The source did not report particular management protocols or intervention dosing; it confined its recommendations to the value of tailored symptom management guided by multidimensional assessment.
The investigators designed the analysis to address earlier limitations in the literature: previous studies of fatigue in prostate cancer had been constrained by small sample sizes and short follow-up intervals. This REQUITE analysis extended follow-up to five years and used a large, prospectively followed cohort to examine both prevalence and longitudinal trajectories. The abstract documents several unanswered clinical questions that remain: which specific interventions reduce distinct MFI dimensions long-term, how interventions should be timed for those in a high-fatigue trajectory, and whether targeted management based on early MFI assessment will change functional or quality-of-life outcomes. The source did not report randomized intervention results or prescriptive clinical pathways.
Limitations directly referenced in the source include the need for more detailed comparative statistics and the historical constraint of prior work by small samples and limited follow-up. The article stops by identifying those gaps as targets for further work rather than presenting interventional data or guideline changes.